Immune Checkpoint Blockade across the Cancer Care Continuum
- 1 June 2018
- journal article
- editorial
- Published by Elsevier BV in Immunity
- Vol. 48 (6), 1077-1080
- https://doi.org/10.1016/j.immuni.2018.06.003
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Emerging biomarkers for immune checkpoint inhibition in lung cancerSeminars in Cancer Biology, 2018
- Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 StudyJournal of Clinical Oncology, 2018
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenThe New England Journal of Medicine, 2018
- Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung CancerThe New England Journal of Medicine, 2018
- Neoadjuvant PD-1 Blockade in Resectable Lung CancerThe New England Journal of Medicine, 2018
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III MelanomaThe New England Journal of Medicine, 2018
- Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic DiseaseCancer Discovery, 2016
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant TherapyThe New England Journal of Medicine, 2016
- Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian CancerCancer Research, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015